Cancer-associated gene abnormalities and chemosensitivity

M. Sakamoto, K. Umayahara, H. Sakamoto, K. Kawasaki, Y. Suehiro, T. Kunugi, T. Akiya, H. Iwabuchi, H. Sakunaga, T. Muroya, Y. Kikuchi, T. Sugishita, Y. Tenjin, Joe Gray, T. Tanaka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

One of the most important clinical issues in cancer chemotherapy is the presence of intrinsic resistance or the appearance of acquired resistance against chemotherapy. As for intrinsic resistance, we had to perform direct chemo-sensitivity testing, or had to rely on the knowledge empirically acquired from randomized clinical trials. However, molecular or genetic markers associated with chemo-sensitivity have been reported recently. For example, inactivation of p53 or GML gene has been reported to be associated with chemo-resistance. Overexpression of topo-isomerase I has been reported to be associated with chemo-sensitivity to Topo I inhibitor. Overexpression of Thymidine Phosphorylase has been found to be associated with chemo-sensitivity to prodrug of 5-FU. By checking the status of such chemo-sensitivity markers prior to chemotherapy, it would be possible to predict the chemotherapeutic effect and even the necessity of the chemotherapy in the near future. In this article, we review the chemo-sensitivity markers reported so far, and methodology contributing to the discovery of new chemo-sensitivity markers. As a clinical study, 11 cases of ovarian cancer with high sensitivity to cisplatin-based chemotherapy and 29 cases of ovarian cancer with chemoresistance were analyzed by Comparative Genomic Hybridization (CGH). Copy number decrease in Xp, and copy number increase in 19q were observed in 13, 12 out of 29 resistant cases (45, 41%) and zero, 1 out of 11 sensitive cases (0, 9%), suggesting that -Xp and +19q were likely to be a genetic event associated with intrinsic drug-resistance (p = 0.006, 0.05, respectively). This effort should contribute to the discovery of new chemo-sensitivity and resistance markers.

Original languageEnglish (US)
Pages (from-to)1819-1831
Number of pages13
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume25
Issue number12
StatePublished - Oct 1998
Externally publishedYes

Fingerprint

Neoplasm Genes
Drug Therapy
Ovarian Neoplasms
Thymidine Phosphorylase
Isomerases
Comparative Genomic Hybridization
Prodrugs
Genetic Markers
Drug Resistance
Fluorouracil
Cisplatin
Molecular Biology
Randomized Controlled Trials
Genes
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Sakamoto, M., Umayahara, K., Sakamoto, H., Kawasaki, K., Suehiro, Y., Kunugi, T., ... Tanaka, T. (1998). Cancer-associated gene abnormalities and chemosensitivity. Gan to kagaku ryoho. Cancer & chemotherapy, 25(12), 1819-1831.

Cancer-associated gene abnormalities and chemosensitivity. / Sakamoto, M.; Umayahara, K.; Sakamoto, H.; Kawasaki, K.; Suehiro, Y.; Kunugi, T.; Akiya, T.; Iwabuchi, H.; Sakunaga, H.; Muroya, T.; Kikuchi, Y.; Sugishita, T.; Tenjin, Y.; Gray, Joe; Tanaka, T.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 25, No. 12, 10.1998, p. 1819-1831.

Research output: Contribution to journalArticle

Sakamoto, M, Umayahara, K, Sakamoto, H, Kawasaki, K, Suehiro, Y, Kunugi, T, Akiya, T, Iwabuchi, H, Sakunaga, H, Muroya, T, Kikuchi, Y, Sugishita, T, Tenjin, Y, Gray, J & Tanaka, T 1998, 'Cancer-associated gene abnormalities and chemosensitivity', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 25, no. 12, pp. 1819-1831.
Sakamoto M, Umayahara K, Sakamoto H, Kawasaki K, Suehiro Y, Kunugi T et al. Cancer-associated gene abnormalities and chemosensitivity. Gan to kagaku ryoho. Cancer & chemotherapy. 1998 Oct;25(12):1819-1831.
Sakamoto, M. ; Umayahara, K. ; Sakamoto, H. ; Kawasaki, K. ; Suehiro, Y. ; Kunugi, T. ; Akiya, T. ; Iwabuchi, H. ; Sakunaga, H. ; Muroya, T. ; Kikuchi, Y. ; Sugishita, T. ; Tenjin, Y. ; Gray, Joe ; Tanaka, T. / Cancer-associated gene abnormalities and chemosensitivity. In: Gan to kagaku ryoho. Cancer & chemotherapy. 1998 ; Vol. 25, No. 12. pp. 1819-1831.
@article{6ab013b66efc4e2b968372108ffdebf9,
title = "Cancer-associated gene abnormalities and chemosensitivity",
abstract = "One of the most important clinical issues in cancer chemotherapy is the presence of intrinsic resistance or the appearance of acquired resistance against chemotherapy. As for intrinsic resistance, we had to perform direct chemo-sensitivity testing, or had to rely on the knowledge empirically acquired from randomized clinical trials. However, molecular or genetic markers associated with chemo-sensitivity have been reported recently. For example, inactivation of p53 or GML gene has been reported to be associated with chemo-resistance. Overexpression of topo-isomerase I has been reported to be associated with chemo-sensitivity to Topo I inhibitor. Overexpression of Thymidine Phosphorylase has been found to be associated with chemo-sensitivity to prodrug of 5-FU. By checking the status of such chemo-sensitivity markers prior to chemotherapy, it would be possible to predict the chemotherapeutic effect and even the necessity of the chemotherapy in the near future. In this article, we review the chemo-sensitivity markers reported so far, and methodology contributing to the discovery of new chemo-sensitivity markers. As a clinical study, 11 cases of ovarian cancer with high sensitivity to cisplatin-based chemotherapy and 29 cases of ovarian cancer with chemoresistance were analyzed by Comparative Genomic Hybridization (CGH). Copy number decrease in Xp, and copy number increase in 19q were observed in 13, 12 out of 29 resistant cases (45, 41{\%}) and zero, 1 out of 11 sensitive cases (0, 9{\%}), suggesting that -Xp and +19q were likely to be a genetic event associated with intrinsic drug-resistance (p = 0.006, 0.05, respectively). This effort should contribute to the discovery of new chemo-sensitivity and resistance markers.",
author = "M. Sakamoto and K. Umayahara and H. Sakamoto and K. Kawasaki and Y. Suehiro and T. Kunugi and T. Akiya and H. Iwabuchi and H. Sakunaga and T. Muroya and Y. Kikuchi and T. Sugishita and Y. Tenjin and Joe Gray and T. Tanaka",
year = "1998",
month = "10",
language = "English (US)",
volume = "25",
pages = "1819--1831",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - Cancer-associated gene abnormalities and chemosensitivity

AU - Sakamoto, M.

AU - Umayahara, K.

AU - Sakamoto, H.

AU - Kawasaki, K.

AU - Suehiro, Y.

AU - Kunugi, T.

AU - Akiya, T.

AU - Iwabuchi, H.

AU - Sakunaga, H.

AU - Muroya, T.

AU - Kikuchi, Y.

AU - Sugishita, T.

AU - Tenjin, Y.

AU - Gray, Joe

AU - Tanaka, T.

PY - 1998/10

Y1 - 1998/10

N2 - One of the most important clinical issues in cancer chemotherapy is the presence of intrinsic resistance or the appearance of acquired resistance against chemotherapy. As for intrinsic resistance, we had to perform direct chemo-sensitivity testing, or had to rely on the knowledge empirically acquired from randomized clinical trials. However, molecular or genetic markers associated with chemo-sensitivity have been reported recently. For example, inactivation of p53 or GML gene has been reported to be associated with chemo-resistance. Overexpression of topo-isomerase I has been reported to be associated with chemo-sensitivity to Topo I inhibitor. Overexpression of Thymidine Phosphorylase has been found to be associated with chemo-sensitivity to prodrug of 5-FU. By checking the status of such chemo-sensitivity markers prior to chemotherapy, it would be possible to predict the chemotherapeutic effect and even the necessity of the chemotherapy in the near future. In this article, we review the chemo-sensitivity markers reported so far, and methodology contributing to the discovery of new chemo-sensitivity markers. As a clinical study, 11 cases of ovarian cancer with high sensitivity to cisplatin-based chemotherapy and 29 cases of ovarian cancer with chemoresistance were analyzed by Comparative Genomic Hybridization (CGH). Copy number decrease in Xp, and copy number increase in 19q were observed in 13, 12 out of 29 resistant cases (45, 41%) and zero, 1 out of 11 sensitive cases (0, 9%), suggesting that -Xp and +19q were likely to be a genetic event associated with intrinsic drug-resistance (p = 0.006, 0.05, respectively). This effort should contribute to the discovery of new chemo-sensitivity and resistance markers.

AB - One of the most important clinical issues in cancer chemotherapy is the presence of intrinsic resistance or the appearance of acquired resistance against chemotherapy. As for intrinsic resistance, we had to perform direct chemo-sensitivity testing, or had to rely on the knowledge empirically acquired from randomized clinical trials. However, molecular or genetic markers associated with chemo-sensitivity have been reported recently. For example, inactivation of p53 or GML gene has been reported to be associated with chemo-resistance. Overexpression of topo-isomerase I has been reported to be associated with chemo-sensitivity to Topo I inhibitor. Overexpression of Thymidine Phosphorylase has been found to be associated with chemo-sensitivity to prodrug of 5-FU. By checking the status of such chemo-sensitivity markers prior to chemotherapy, it would be possible to predict the chemotherapeutic effect and even the necessity of the chemotherapy in the near future. In this article, we review the chemo-sensitivity markers reported so far, and methodology contributing to the discovery of new chemo-sensitivity markers. As a clinical study, 11 cases of ovarian cancer with high sensitivity to cisplatin-based chemotherapy and 29 cases of ovarian cancer with chemoresistance were analyzed by Comparative Genomic Hybridization (CGH). Copy number decrease in Xp, and copy number increase in 19q were observed in 13, 12 out of 29 resistant cases (45, 41%) and zero, 1 out of 11 sensitive cases (0, 9%), suggesting that -Xp and +19q were likely to be a genetic event associated with intrinsic drug-resistance (p = 0.006, 0.05, respectively). This effort should contribute to the discovery of new chemo-sensitivity and resistance markers.

UR - http://www.scopus.com/inward/record.url?scp=0032185468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032185468&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 1819

EP - 1831

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -